Today’s Statin Debate Bears Lessons For Tomorrow’s Cholesterol Drugs

Clinicians recently took to the pages of the Journal of the American Medical Association to argue the appropriateness of using statin therapy as primary prevention in patients who are not already at high risk for a cardiovascular event. Such scrutiny comes as NIH prepares to issue new treatment guidelines to a market newly saturated with popular generic options, and as pharmaceutical companies assess how best to approach the dyslipidemia field.